Cargando…

Clinical Significance of Determining Plasma MicroRNA33b in Type 2 Diabetic Patients with Dyslipidemia

Aim: Sterol regulatory element-binding protein (SREBP)-1c is the dominant liver insulin-stimulated isoform and strongly correlates with diabetic dyslipidemia characterized by hyperinsulinemia [i.e., high-density lipoprotein cholesterol (HDL-C) levels and hypertriglyceridemia]. MicroRNA (miRNA) 33b i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Yuki, Tamasawa, Naoki, Matsumura, Koki, Murakami, Hiroshi, Yamashita, Maki, Matsuki, Kota, Tanabe, Jutaro, Matsui, Jun, Daimon, Makoto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5113745/
https://www.ncbi.nlm.nih.gov/pubmed/27301461
http://dx.doi.org/10.5551/jat.33670
_version_ 1782468238462943232
author Kimura, Yuki
Tamasawa, Naoki
Matsumura, Koki
Murakami, Hiroshi
Yamashita, Maki
Matsuki, Kota
Tanabe, Jutaro
Murakami, Hiroshi
Matsui, Jun
Daimon, Makoto
author_facet Kimura, Yuki
Tamasawa, Naoki
Matsumura, Koki
Murakami, Hiroshi
Yamashita, Maki
Matsuki, Kota
Tanabe, Jutaro
Murakami, Hiroshi
Matsui, Jun
Daimon, Makoto
author_sort Kimura, Yuki
collection PubMed
description Aim: Sterol regulatory element-binding protein (SREBP)-1c is the dominant liver insulin-stimulated isoform and strongly correlates with diabetic dyslipidemia characterized by hyperinsulinemia [i.e., high-density lipoprotein cholesterol (HDL-C) levels and hypertriglyceridemia]. MicroRNA (miRNA) 33b is harbored in the intron of SREBP-1c and represses ATP-binding cassette, sub-family A, and member 1 (ABCA1) expression, essential for HDL formation. We measured plasma miRNA33b levels as possible biomarkers for diabetic dyslipidemia in patients with type 2 diabetes mellitus (T2DM) showing insulin resistance. Methods: The participants included 50 patients with T2DM (M/F 31/19) enrolled in an educational program for controlling blood glucose levels at Hirosaki University Hospital. HbA1c, fasting plasma glucose, insulin, and lipid levels were determined. Plasma miRNA33b, miRNA33a and miRNA148a were quantified using a TaqMan(®) MicroRNA Assay, and values were corrected with reference to miRNA16. Results: Mean BMI of participants were 28.2 ± 6.6 (kg/m(2)) and the Homeostasis Model Assessment of Insulin Resistance was 4.3 ± 2.7. Patients' laboratory findings indicated diabetic dyslipidemia with insulin resistance. Plasma miRNA33b/16 levels revealed a positive correlation with plasma insulin level (r = 0.326, P = 0.021), serum C-peptide (r = 0.280, P = 0.049), and triglyceride (r = 0.351, P = 0.012), but no association with HDL-C (r = −0.210, P = 0.143). The blood level of miRNA33a was approximately 1/150th of that of miRNA33b and was not correlated with the above parameters. Conclusion: We postulated that plasma miRNA33b may be useful as a new metabolic biomarker of dyslipidemia in patients with T2DM as well as metabolic syndrome via an insulin/SREBP-1c/miRNA33b/ABCA1 pathway.
format Online
Article
Text
id pubmed-5113745
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Japan Atherosclerosis Society
record_format MEDLINE/PubMed
spelling pubmed-51137452016-11-21 Clinical Significance of Determining Plasma MicroRNA33b in Type 2 Diabetic Patients with Dyslipidemia Kimura, Yuki Tamasawa, Naoki Matsumura, Koki Murakami, Hiroshi Yamashita, Maki Matsuki, Kota Tanabe, Jutaro Murakami, Hiroshi Matsui, Jun Daimon, Makoto J Atheroscler Thromb Original Article Aim: Sterol regulatory element-binding protein (SREBP)-1c is the dominant liver insulin-stimulated isoform and strongly correlates with diabetic dyslipidemia characterized by hyperinsulinemia [i.e., high-density lipoprotein cholesterol (HDL-C) levels and hypertriglyceridemia]. MicroRNA (miRNA) 33b is harbored in the intron of SREBP-1c and represses ATP-binding cassette, sub-family A, and member 1 (ABCA1) expression, essential for HDL formation. We measured plasma miRNA33b levels as possible biomarkers for diabetic dyslipidemia in patients with type 2 diabetes mellitus (T2DM) showing insulin resistance. Methods: The participants included 50 patients with T2DM (M/F 31/19) enrolled in an educational program for controlling blood glucose levels at Hirosaki University Hospital. HbA1c, fasting plasma glucose, insulin, and lipid levels were determined. Plasma miRNA33b, miRNA33a and miRNA148a were quantified using a TaqMan(®) MicroRNA Assay, and values were corrected with reference to miRNA16. Results: Mean BMI of participants were 28.2 ± 6.6 (kg/m(2)) and the Homeostasis Model Assessment of Insulin Resistance was 4.3 ± 2.7. Patients' laboratory findings indicated diabetic dyslipidemia with insulin resistance. Plasma miRNA33b/16 levels revealed a positive correlation with plasma insulin level (r = 0.326, P = 0.021), serum C-peptide (r = 0.280, P = 0.049), and triglyceride (r = 0.351, P = 0.012), but no association with HDL-C (r = −0.210, P = 0.143). The blood level of miRNA33a was approximately 1/150th of that of miRNA33b and was not correlated with the above parameters. Conclusion: We postulated that plasma miRNA33b may be useful as a new metabolic biomarker of dyslipidemia in patients with T2DM as well as metabolic syndrome via an insulin/SREBP-1c/miRNA33b/ABCA1 pathway. Japan Atherosclerosis Society 2016-11-01 /pmc/articles/PMC5113745/ /pubmed/27301461 http://dx.doi.org/10.5551/jat.33670 Text en 2016 Japan Atherosclerosis Society This article is distributed under the terms of the latest version of CC BY-NC-SA defined by the Creative Commons Attribution License.
spellingShingle Original Article
Kimura, Yuki
Tamasawa, Naoki
Matsumura, Koki
Murakami, Hiroshi
Yamashita, Maki
Matsuki, Kota
Tanabe, Jutaro
Murakami, Hiroshi
Matsui, Jun
Daimon, Makoto
Clinical Significance of Determining Plasma MicroRNA33b in Type 2 Diabetic Patients with Dyslipidemia
title Clinical Significance of Determining Plasma MicroRNA33b in Type 2 Diabetic Patients with Dyslipidemia
title_full Clinical Significance of Determining Plasma MicroRNA33b in Type 2 Diabetic Patients with Dyslipidemia
title_fullStr Clinical Significance of Determining Plasma MicroRNA33b in Type 2 Diabetic Patients with Dyslipidemia
title_full_unstemmed Clinical Significance of Determining Plasma MicroRNA33b in Type 2 Diabetic Patients with Dyslipidemia
title_short Clinical Significance of Determining Plasma MicroRNA33b in Type 2 Diabetic Patients with Dyslipidemia
title_sort clinical significance of determining plasma microrna33b in type 2 diabetic patients with dyslipidemia
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5113745/
https://www.ncbi.nlm.nih.gov/pubmed/27301461
http://dx.doi.org/10.5551/jat.33670
work_keys_str_mv AT kimurayuki clinicalsignificanceofdeterminingplasmamicrorna33bintype2diabeticpatientswithdyslipidemia
AT tamasawanaoki clinicalsignificanceofdeterminingplasmamicrorna33bintype2diabeticpatientswithdyslipidemia
AT matsumurakoki clinicalsignificanceofdeterminingplasmamicrorna33bintype2diabeticpatientswithdyslipidemia
AT murakamihiroshi clinicalsignificanceofdeterminingplasmamicrorna33bintype2diabeticpatientswithdyslipidemia
AT yamashitamaki clinicalsignificanceofdeterminingplasmamicrorna33bintype2diabeticpatientswithdyslipidemia
AT matsukikota clinicalsignificanceofdeterminingplasmamicrorna33bintype2diabeticpatientswithdyslipidemia
AT tanabejutaro clinicalsignificanceofdeterminingplasmamicrorna33bintype2diabeticpatientswithdyslipidemia
AT murakamihiroshi clinicalsignificanceofdeterminingplasmamicrorna33bintype2diabeticpatientswithdyslipidemia
AT matsuijun clinicalsignificanceofdeterminingplasmamicrorna33bintype2diabeticpatientswithdyslipidemia
AT daimonmakoto clinicalsignificanceofdeterminingplasmamicrorna33bintype2diabeticpatientswithdyslipidemia